New
HealthMore in Health→
Oral GLP-1 Pill Safiglipron Cuts HbA1c in Early Type 2 Diabetes Trial
Key Takeaways
- OUTSTAND-1 was a randomized, double-blind, placebo-controlled trial of once-daily oral safiglipron in early type 2 diabetes.
- The trial reported that safiglipron, a small-molecule GLP-1 receptor agonist, reduced HbA1c.
- Results were published in Nature Medicine on 29 September 2026 (doi:10.1038/s41591-026-04651-9).
- An oral small molecule could offer manufacturing, distribution, and patient-acceptance advantages over injectable peptide GLP-1 therapies.
DE
DT Editorial Team··via nature.com